The complement system is a series of serum proteins that perform cell lytic and pro-inflammatory functions as part of the bodies mechanism for removing foreign, dead or damaged cells.
The complement system consists of the alternative and classical pathways. During activation the anaphylatoxins C4a and C3a are released and these can be measured using competitive MAS.
Abherrant activation of the complement system has been implicated in a number of disease states e.g. acute lung injury, severe bums, myocardial injury and inflammatory diseases.
During mechanistic studies on synthetic complement inhibitors it was observed that dimethyl sulfoxide (DMSO) was able to activate complement. This was an important observation because DMSO and other organic solvents are used routinely in phannaceutics and blood fractionation applications where complement activation is undesirable.
This study explored the complement activation properties of DMSO and Ethanol, in human sera and was extended to include the use of recombinant human complement receptor type l(sCRl), a known complement inhibitor [l] , to elucidate which complement pathways were involved.
Human sera pooled from a screened panel of healthy volunteers was used in this study. Complement activation was monitored using a modified competitive RIA specific for C3a or C4a [2] .
Undiluted serum samples were incubated for 60 mins at 37.C. and anaphylatoxin levels measured pre and post-incubation. Solvents used throughout this study were HPLC or ANALAR grade.
Solvents were pre-diluted in HEPES buffer and fixed volumes added to the sera to minimize dilution effects. A single batch of sCRl was used throughout this study and added to the serum at various concentrations prior to the addition of solvent. Serum free control samples were incubated for 60 mins at 37'C to eliminate solvent assay artifacts.
DMSO and ethanol at concentrations ranging from 0-4% v/v generated raised levels of C3a (30-401g/ml) indicating complement activation approximately half that of the theoretical maximum for human serum (Figure 1) . The C3a release initiated by both solvents was clearly concentration dependent and occurred after 1 hr incubation at 37'C. DMSO and Ethanol tested in the absence of serum did not raise C3a levels (data not shown).
A solvent concentration of 4% v/v was chosen for further studies with sCR1. At sCRl concentrations between 0.1 and 100 pdml significant inhibition of the DMSO-mediated rise in C3a levels was observed (Figure 2) . The IC50% for C3a inhibition was - To ascertain which complement pathway(s) were activated by DMSO, a specific marker of classical pathway activation (C4a) was measured. DMSO did not cause an increase of C4a indicating the alternative pathway of complement was activated (Figure 3) .
The activation of complement by relatively low levels of the organic solvents DMSO and Ethanol is an apparently novel observation The observation is potentially important since both DMSO and Ethanol are routinely used in phannaceutics and preparation of blood products.
The demonstration that sCRl inhibits the solvent-mediated effects suggests its use may be beneficial in controlling aberrant complement activation in the above applications.
A possible mode of action for the solvent-mediated activation of complement is through inhibition of one of the regulatory proteins of the alternative pathway. One such protein is Factor I. Inhibition of Factor I would lead to exhaustive cycling of the amplification loop of the alternative pathway and the generation of large amounts of C3a.
